(Q81585612)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

metastatic prostate carcinoma

10 January 2020

main subject

1 reference

6

Anthony V D'Amico

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Flora Rozhansky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Ming-Hui Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Michael C Cox

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

William Dahut

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

William D Figg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

63-67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21576

7 January 2021

Identifiers

DOI

10.1002/CNCR.21576

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16333854%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference